TO TORNTPHARM
Torrent Pharmaceuticals Q1 2027
TOTORNTPHARM

Torrent Pharmaceuticals Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 30 Jul 2026

Management summary

  • Torrent Pharmaceuticals reported robust Q1 FY27 results.
  • Strong growth across both the acquired JB business and its base operations, leading to significant revenue and EBITDA expansion..
  • The company is ahead on cost synergy realization from the JB merger.
  • However, a temporary supply issue for the semaglutide injectable and challenges in the Germany market present short-term headwinds.
  • Integration activities are expected to cause transient revenue impacts..

Source: Inve concall analysis and management guidance record.

Highlights

  • Consolidated revenues grew 55% YoY to INR4,921 crores.

  • Operating EBITDA increased 61% YoY to INR1,664 crores, with a margin of 33.8%.

  • JB business revenues grew 10% YoY to INR1,201 crores, with an EBITDA margin of 35.3%.

  • Torrent base business revenues grew 17% YoY, with India business up 19% and Brazil up 27%.

What they filed

Q1 FY27: revenue up 58.9%, net profit down 10.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue2,377 2,433 2,616 2,762 2,599 +9%3,445 +42%4,158 +59%
EBITDA887 868 979 1,072 1,000 +13%1,228 +41%1,573 +61%
Net profit485 474 551 597 577 +19%309 −35%492 −11%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • JB Overall Business Constant Currency Growth Revenue · full year · High confidence high single-digit to low double-digit

Market context

  • JB India Rx Business Revenue Growth Revenue · FY27 · High confidence double-digit

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

2 direct
JB Pharma Profitability & Cost Synergies Direct
Yeah, I would say the margin improvement is largely because of the cost synergies being implemented sooner than expected.

Clarifies the primary driver behind the strong profitability of the acquired JB business, indicating successful and accelerated synergy realization.

Asked by Kunal Dhamesha

Brazil Channel Inventory Correction & Growth Outlook Direct
Correct. So, we expect the normalized growth rate to come back to again mid-teens level growth as reflected in the IQVIA data.

Explains a temporary drag on Brazil sales due to inventory correction and provides a clear forward growth expectation for the market.

Asked by Kunal Dhamesha

Unlock risks & concerns, Q2 FY27 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 7 risks, concerns & management red flags
  • 5 watchlist triggers for Q2 FY27
  • +9 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image